Proteomic and transcriptomic screening demonstrates increased mast cell–derived CCL23 in systemic mastocytosis - 05/07/23
Graphical abstract |
Abstract |
Background |
Systemic mastocytosis (SM) is a heterogeneous group of mast cell–driven diseases diagnosed by bone marrow sampling. However, there are a limited number of available blood disease biomarkers.
Objective |
Our aim was to identify mast cell–derived proteins that could potentially serve as blood biomarkers for indolent and advanced forms of SM.
Methods |
We performed a plasma proteomics screening coupled with single-cell transcriptomic analysis in SM patients and healthy subjects.
Results |
Plasma proteomics screening identified 19 proteins upregulated in indolent disease compared to healthy, and 16 proteins in advanced disease compared to indolent. Among these, 5 proteins, CCL19, CCL23, CXCL13, IL-10, and IL-12Rβ1, were higher in indolent relative to healthy and in advanced disease compared to indolent. Single-cell RNA sequencing demonstrated that CCL23, IL-10, and IL-6 were selectively produced by mast cells. Notably, plasma CCL23 levels correlated positively with known markers of SM disease severity, namely tryptase levels, percentage bone marrow mast cell infiltration, and IL-6.
Conclusion |
CCL23 is produced predominantly by mast cells in SM, and CCL23 plasma levels are associated with disease severity, correlating positively with established markers of disease burden, thus suggesting that CCL23 is a specific SM biomarker. In addition, the combination of CCL19, CCL23, CXCL13, IL-10, and IL-12Rβ1 may be useful for defining disease stage.
Le texte complet de cet article est disponible en PDF.Key words : Systemic mastocytosis, CCL23, IL-10, IL-6, biomarkers, single-cell transcriptomics, plasma proteomics
Abbreviations used : AdvSM, CM, HC, IL-12Rβ1, ISM, MNC, NPX, PCA, SM, UMAP
Plan
| Supported by Uppsala University Hospital (S.S.), the Lions Cancer Research Fund Uppsala (S.S.), the Swedish Society of Medicine (S.S.), the Swedish Cancer Society (J.U. and J.S.D.), the Stockholm Cancer Association Radiumhemmet (J.U.), the Swedish Research Council (2018-02070 to J.S.D.), the Åke Wiberg Foundation (J.S.D.), Magnus Bergvall’s Foundation (J.S.D.), and Karolinska Institutet. |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
Vol 152 - N° 1
P. 205-213 - juillet 2023 Retour au numéro
Article précédent
- The Hdc GC box is critical for Hdc gene transcription and histamine-mediated anaphylaxis
- Yapeng Li, Junfeng Gao, Dianzheng Zhao, Xiaoyu Guan, Suzanne C. Morris, Fred D. Finkelman, Hua Huang
- Clonal evolution and stereotyped sequences of human IgE lineages in aeroallergen-specific immunotherapy
- Ramona A. Hoh, Linnea Thörnqvist, Fan Yang, Magdalena Godzwon, Jasmine J. King, Ji-Yeun Lee, Lennart Greiff, Scott D. Boyd, Mats Ohlin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?